Expertise in
30
conditions

Dr. Edwin C. Kingsley

Allison Curtis Kingsley Meoz Michael And Sanchez PC
Las Vegas, NV
Expertise in
30
conditions
Specialties:Hematology Oncology | Oncology | Hematology
Offers Telehealth
Expertise in
30
conditions
OverviewInsuranceLocationsClinical Research

Overview

Edwin Kingsley is a Hematologist Oncology specialist and an Oncologist in Las Vegas, Nevada. Dr. Kingsley is highly rated in 30 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Pleuropulmonary Blastoma, Lung Cancer, and Follicular Lymphoma.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NV
Hospital Affiliations
Sunrise Hospital And Medical Center
Mountainview Hospital
Southern Hills Hospital And Medical Center
Saint Rose Dominican Hospitals - Siena Campus
Kingman Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

ALLISON CURTIS KINGSLEY MEOZ MICHAEL AND SANCHEZ PC
3730 S Eastern Ave, Las Vegas, NV 89169
702-952-3400

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Obinutuzumab
Study Phase: Phase 2
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2024
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

10 Total Publications

ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 28, 2023
Similar Doctors
Wolfram E. Samlowski
Expertise in
19
conditions
Dr. Wolfram E. Samlowski
Hematology Oncology | Hematology | Oncology
Expertise in
19
conditions
Dr. Wolfram E. Samlowski
Hematology Oncology | Hematology | Oncology

Allison Curtis Kingsley Meoz Michael And Sanchez PC

9280 W Sunset Rd, Suite 100, 
Las Vegas, NV 
 (10.4 mi)
702-952-1251
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Wolfram Samlowski is a Hematologist Oncology specialist and a Hematologist in Las Vegas, Nevada. Dr. Samlowski is highly rated in 19 conditions, according to our data. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Renal Cell Carcinoma (RCC), and Angiosarcoma of the Scalp.

Clark S. Jean
Expertise in
57
conditions
Dr. Clark S. Jean
Hematology Oncology | Oncology | Hematology
Expertise in
57
conditions
Dr. Clark S. Jean
Hematology Oncology | Oncology | Hematology

Allison Curtis Kingsley Meoz Michael And Sanchez PC

7445 Peak Dr, 
Las Vegas, NV 
 (9.8 mi)
702-952-2140
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Clark Jean is a Hematologist Oncology specialist and an Oncologist in Las Vegas, Nevada. Dr. Jean is highly rated in 57 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Colorectal Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Expertise in
18
conditions
Dr. Nicholas J. Vogelzang
Hematology Oncology
Expertise in
18
conditions
Dr. Nicholas J. Vogelzang
Hematology Oncology
3730 S Eastern Ave, 
Las Vegas, NV 
702-952-3400
Languages Spoken:
English
See accepted insurances

Nicholas Vogelzang is a Hematologist Oncology provider in Las Vegas, Nevada. Dr. Vogelzang is highly rated in 18 conditions, according to our data. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Orchiectomy, and Nephrectomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile